Frank T Zenke

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 14

Top Topics

Circulating Tumor

Dna Damage Response

Top Venues

Molecular cancer therapeutics

Nature communications

Molecular cancer research : MCR

Cancer research

This page only lists publications with an associated author ORCID identifier.

Publications

Ukhyun Jo, Yashuhiro Arakawa, Astrid Zimmermann, Daiki Taniyama, Makito Mizunuma, Lisa M Miller Jenkins, Tapan Maity, Suresh Kumar, Frank T Zenke, Naoko Takebe, Yves Pommier
The novel ATR inhibitor M1774 induces replication protein overexpression and broad synergy with DNA-targeted anticancer drugs. Molecular cancer therapeutics (2024)
Ukhyun Jo, Yashuhiro Arakawa, Astrid Zimmermann, Daiki Taniyama, Makito Mizunuma, Lisa M Miller Jenkins, Tapan Maity, Suresh Kumar, Frank T Zenke, Naoko Takebe, Yves Pommier
The Novel ATR Inhibitor M1774 Induces Replication Protein Overexpression and Broad Synergy with DNA-targeted Anticancer Drugs. Molecular cancer therapeutics 23 (7) (2024)
Hanrui Zhang, Julian Kreis, Sven-Eric Schelhorn, Heike Dahmen, Thomas Grombacher, Michael Zühlsdorf, Frank T Zenke, Yuanfang Guan
Mapping combinatorial drug effects to DNA damage response kinase inhibitors. Nature communications 14 (1) (2023)
Manja Friese-Hamim, Maria J Ortiz-Ruiz, Olga Bogatyrova, Marina Keil, Felix Rohdich, Beatrix Blume, Birgitta Leuthner, Frank Czauderna, Diane Hahn, Julia Jabs, Frank Jaehrling, Timo Heinrich, Roland Kellner, Katherine Chan, Amy H Y Tong, Dirk Wienke, Jason Moffat, Andree Blaukat, Frank T Zenke
Novel Methionine Aminopeptidase 2 Inhibitor M8891 Synergizes with VEGF Receptor Inhibitors to Inhibit Tumor Growth of Renal Cell Carcinoma Models. Molecular cancer therapeutics (2023)
Hanrui Zhang, Julian Kreis, Sven-Eric Schelhorn, Heike Dahmen, Thomas Grombacher, Michael Zühlsdorf, Frank T Zenke, Yuanfang Guan
Mapping combinatorial drug effects to DNA damage response kinase inhibitors. Nature communications 14 (1) (2023)
Audrey Turchick, Astrid Zimmermann, Li-Ya Chiu, Heike Dahmen, Brian Elenbaas, Frank T Zenke, Andree Blaukat, Lyubomir T Vassilev
Selective inhibition of ATM-dependent double-strand break repair and checkpoint control synergistically enhances the efficacy of ATR inhibitors. Molecular cancer therapeutics (2023)
Hanrui Zhang, Julian Kreis, Sven-Eric Schelhorn, Heike Dahmen, Thomas Grombacher, Michael Zühlsdorf, Frank T Zenke, Yuanfang Guan
Mapping combinatorial drug effects to DNA damage response kinase inhibitors. Nature communications 14 (1) (2023)
Adrian Mariño-Enriquez, Jan Philipp Novotny, Doga C Gulhan, Isabella Klooster, Antuan V Tran, Macy Kasbo, Meijun Z Lundberg, Wen-Bin Ou, Derrick L Tao, Daniel F Pilco-Janeta, Victor Y Mao, Frank T Zenke, Brittaney A Leeper, Prafulla C Gokhale, Glenn S Cowley, Laurence H Baker, Karla V Ballman, David E Root, Joachim Albers, Peter J Park, Suzanne George, Jonathan A Fletcher
Hyper-Dependence on NHEJ Enables Synergy Between DNA-PK Inhibitors and Low-Dose Doxorubicin in Leiomyosarcoma. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Hanrui Zhang, Julian Kreis, Sven-Eric Schelhorn, Heike Dahmen, Thomas Grombacher, Michael Zühlsdorf, Frank T Zenke, Yuanfang Guan
Mapping combinatorial drug effects to DNA damage response kinase inhibitors. Nature communications 14 (1) (2023)
Marta J Llorca-Cardenosa, Lauren I Aronson, Dragomir B Krastev, Jadwiga Nieminuszczy, John Alexander, Feifei Song, Malgorzata Dylewska, Ronan Broderick, Rachel Brough, Astrid Zimmermann, Frank T Zenke, Bora Gurel, Ruth Riisnaes, Ana Ferreira, Theodoros I Roumeliotis, Jyoti Sharma Choudhary, Stephen J Pettitt, Johann S de Bono, Andres Cervantes, Syed Haider, Wojciech Niedzwiedz, Christopher J Lord, Irene Y Chong
SMG8/SMG9 Heterodimer Loss Modulates SMG1 Kinase to Drive ATR Inhibitor Resistance. Cancer research 82 (21) (2022)
Astrid Zimmermann, Frank T Zenke, Li-Ya Chiu, Heike Dahmen, Ulrich Pehl, Thomas Fuchss, Thomas Grombacher, Beatrix Blume, Lyubomir T Vassilev, Andree Blaukat
A New Class of Selective ATM Inhibitors as Combination Partners of DNA Double-Strand Break Inducing Cancer Therapies. Molecular cancer therapeutics 21 (6) (2022)
Michael I Carr, Li-Ya Chiu, Yige Guo, Chunxiao Xu, Adam S Lazorchak, Huakui Yu, Guozhong Qin, Jin Qi, Bo Marelli, Yan Lan, Qing Sun, Frank Czauderna, Frank T Zenke, Andree Blaukat, Lyubomir T Vassilev
DNA-PK Inhibitor Peposertib Amplifies Radiation-Induced Inflammatory Micronucleation and Enhances TGFβ/PD-L1 Targeted Cancer Immunotherapy. Molecular cancer research : MCR 20 (4) (2022)
Ukhyun Jo, Ilya S Senatorov, Astrid Zimmermann, Liton Kumar Saha, Yasuhisa Murai, Se Hyun Kim, Vinodh N Rajapakse, Fathi Elloumi, Nobuyuki Takahashi, Christopher W Schultz, Anish Thomas, Frank T Zenke, Yves Pommier
Novel and Highly Potent ATR Inhibitor M4344 Kills Cancer Cells With Replication Stress, and Enhances the Chemotherapeutic Activity of Widely Used DNA Damaging Agents. Molecular cancer therapeutics 20 (8) (2021)
Paris Roidos, Stephanie Sungalee, Salvatore Benfatto, Özdemirhan Serçin, Adrian M Stütz, Amir Abdollahi, Jan Mauer, Frank T Zenke, Jan O Korbel, Balca R Mardin
A scalable CRISPR/Cas9-based fluorescent reporter assay to study DNA double-strand break repair choice. Nature communications 11 (1) (2020)